Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival

Radiology

Volumn 258, Issue 2, 2011, Pages 627-634

  Chung, Goh Eun ^a   Lee, Jeong Hoon ^b   Kim, Hwi Young ^b   Hwang, Sang Youn ^b   Kim, Joon Suk ^b   Chung, Jin Wook ^b   Yoon, Jung Hwan ^b   Lee, Hyo Suk ^b   Kim, Yoon Jun ^b  

^a Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ASCITES; BACTEREMIA; BACTERIAL PERITONITIS; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LUNG EMBOLISM; MAIN PORTAL VEIN INVASION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARALYTIC ILEUS; PATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; REPEAT PROCEDURE; SUPPORTIVE CARE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DOXORUBICIN; ETHIODIZED OIL; FEMALE; GELATIN SPONGE, ABSORBABLE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; PORTAL VEIN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79952341136     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10101058     Document Type: Article

References (27)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557-2576. (Pubitemid 46890874)
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108.
3. Bruix J, Sherman M;Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-1236.
4. Lladó L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88(1):50-57. (Pubitemid 30027678)
5. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006;12(47):7561-7567. (Pubitemid 46040565)
6. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-1739. (Pubitemid 34607087)
7. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37(2):429-442. (Pubitemid 36152543)
8. Jeon SH, Park KS, Kim YH, et al. Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma [in Korean]. Korean J Gastroenterol 2007;50(3):176-182.
9. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(suppl 1):S20-S37.
10. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials - II-systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 2004;15(5):439-452. (Pubitemid 38736941)
11. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390.
12. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16(12):1653- 1659. (Pubitemid 44431162)
13. Kim KM, Kim JH, Park IS, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009;24(5):806-814.
14. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 1997;79(11):2087-2094. (Pubitemid 27227372)
15. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995;165(2):315-321.
16. Yoon JH, Kim HC, Chung JW, Yoon JH, Jae HJ, Park JH. CT findings of completely regressed hepatocellular carcinoma with main portal vein tumor thrombosis after transcatheter arterial chemoembolization. Korean J Radiol 2010;11(1):69-74.
17. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002;87(7):13-15.
18. Buijs M, Vossen JA, Frangakis C, et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology 2008;249(1):346-354.
19. Shim JH, Park JW, Choi JI, Kim HB, Lee WJ, Kim CM. Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma? J Vasc Interv Radiol 2009;20(2):209-216.
20. National Cancer Institute. Common terminology criteria for adverse events, version 3.0. Available at http://ctep.cancer.gov/reporting/ctc.html. Published August 9, 2006. Accessed August 2010.
21. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 suppl 1):S179-S188. (Pubitemid 39423386)
22. Uka K, Aikata H, Takaki S, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007;13(3):414-420. (Pubitemid 46178976)
23. Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2009;20(7 suppl):S219-S226, S226.e1-S226.e10.
24. Chung JW, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198(1):33-40.
25. Kiely JM, Rilling WS, Touzios JG, et al. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol 2006;17(1):47-53. (Pubitemid 44392032)
26. Song B, Min P, Oudkerk M, et al. Cavernous transformation of the portal vein secondary to tumor thrombosis of hepatocellular carcinoma: spiral CT visualization of the collateral vessels. Abdom Imaging 2000;25(4 ): 385-393. (Pubitemid 30439621)
27. Pentecost MJ, Daniels JR, Teitelbaum GP, Stanley P. Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Interv Radiol 1993;4(3):347-351.